StreetAlpha.app
Home › Stocks › CERS

Cerus Corp (CERS)

Healthcare
$1.90
▲ +2.15%
LAST CLOSE · NOV 17

Cerus makes the INTERCEPT Blood System, which is used to reduce pathogens in donated blood components for transfusion. It last closed at $1.90 on Nov 17, up 2.15% on the day.

AI Auto Pilots
Is CERS in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$254.2M
Net income
−$7.3M
−2.9% margin
EPS (diluted)
−$0.04
Free cash flow
$494K
0.2% margin
Valuation
Market cap
$383.7M
202.0M shares
P/E
–
No P/E while losing money
Price to sales
1.5
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$16.4M
At Sep 30
Shareholder equity
$75.7M
Shares outstanding
202.0M
At Oct 16
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $159.5M$159.5MFY2021FY2022: $188.3M$188.3MFY2022FY2023: $186.8M$186.8MFY2023FY2024: $201.3M$201.3MFY2024FY2025: $233.8M$233.8MFY2025

From CERS's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 2). Last 12 months adds up the four latest quarters.

Next report
—
No date on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
1 Buy
1 firm · not enough for a consensus
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Ratings · 90 days
1 Buy
1firm
1 Buy0 Hold0 Sell
Only 1 firm rated CERS in the past 90 days, not enough for a consensus
Average 12-month target
$6.50
▲ 242.1% upside

Based on 1 analyst who set a price target on CERS in the past 90 days. The average target is $6.50, with a high of $6.50 and a low of $6.50, compared with the last close of $1.90.

Low $6.50Avg $6.50High $6.50
Blue marker: last close $1.90
Highest target$6.50
Average target$6.50
Lowest target$6.50
Latest rating changes
Freedom BrokerInitiated
Aug 20Buy$6.50
BTIGUpgrade
May 1Buy$4
DateFirmActionRatingPrice target
Aug 20Freedom BrokerInitiatedBuy$6.50
May 1BTIGUpgradeBuy$4
Loading…

Technical Analysis

CERS · as of the Nov 17 close · updated after every close
Downtrend, nearing oversold

The stock is 16% below its 20 day and 23% below its 50 day average. It is 28% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 37), near oversold. The nearest support is the Pivot at $1.89, and the nearest resistance the Pivot R1 at $1.94.

Short trendBearish
Long trendBearish
MomentumWeak
StretchNear oversold
VolatilityHigh, 7.5%/day
Key levels
$3.4752 week high+82.6%
$2.57100 day average+35.3%
$2.43200 day average+27.9%
$2.3350 day average+22.6%
$2.2020 day average+15.8%
$2.16Swing high (Nov 11)+13.7%
$1.94Pivot R1+2.1%
$1.90Last close
$1.89Pivot−0.5%
$1.85Pivot S1−2.6%
$1.4752 week low−22.6%
Indicators
RSI (14)36.95Weak, oversold below 30Neutral
MACD-0.12Below its signal lineBearish
Stochastic8.5Near the bottom of its rangeOversold
ADX (14)27.9Trending down
Williams %R-90.5Oversold below −80, overbought above −20Oversold
CCI (20)-118.1Oversold below −100, overbought above 100Oversold
Rate of change−18.8%Change over 10 sessionsBearish
ATR (14)$0.14Typical daily range, 7.5% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for CERS

What happened before

See how CERS did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow CERS usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How CERS has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2006.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in CERS in the last 90 days.

Loading…

See today’s whale options flow across the market →

CERS Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bearish
Strongly bearishNeutralStrongly bullish
  • ▼75 buying vs 103 selling
  • ▲Held by funds +3.0 pts
  • ▼Funds holding -8
  • ▼Superinvestors: 2 added, 3 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding179187−4.3%
In funds' top 1000–
Held by funds77.6%74.6%+3.0 pts
New / increased24 / 5136 / 71−29.9%
Reduced / sold out71 / 3253 / 16+49.3%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See CERS institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether CERS is in one of them and how their past CERS trades turned out.

CERS in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered CERS in an article yet. Here's the latest on the wider market.

About Cerus

Cerus is a biomedical products company based in Concord, California. Its main product is the INTERCEPT Blood System, which is designed to reduce bloodborne pathogens in donated blood components intended for transfusion. The system is used to treat platelets and plasma, and a related version produces a fibrinogen complex for treating bleeding linked to fibrinogen deficiency. Cerus sells these products through its own sales force and distributors in several countries, while its red blood cell system remains in development.

Headquarters
Concord, CA